Eptifibatide
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 831.96 |
| Cas No. | 188627-80-7 |
| Formula | C35H49N11O9S2 |
| Solubility | ≥28.7 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
| Chemical Name | 2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-((diaminomethylene)amino)butyl)-1,9,12,15,18,21-hexaoxodocosahydro-1H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl)acetic acid |
| SDF | Download SDF |
| Canonical SMILES | O=C([C@@](C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12)([H])N([H])C([C@@](C([H])([H])C(O[H])=O)([H])N([H])C(C([H])([H])N([H])C3=O)=O)=O)N4[C@@](C(N([H])[C@@](C(N([H])[H])=O)([H])C([H])([H])SSC([H])([H])C([H])([H])C(N([H])[C@@]3([H])C([H])([H |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1, 2]: | |
|
Cell lines |
Activated platelets and leukocytes |
|
Preparation method |
The solubility of this compound in DMSO is >28.7 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.0625-1.5 w g/ml |
|
Applications |
Eptifibatide dose-dependently enhanced (0.0625-1.5 w g/ml) both collagen-induced platelet-monocyte (P/M) formation and monocyte TF expression with maximum enhancement about 60 and 120%, respectively, at 0.5 w g/ml eptifibatide. Eptifibatide had only a minor effect on platelet-neutrophil (P/N) formation and no effect on neutrophil TF expression. Eptifibatide dose-dependently reduced ADP, collagen, and thrombin-induced platelet aggregation (IC50 = 16-27 mg/mL), dense granule secretion (IC50 = 22-31 mg/mL) and lysosome secretion (IC50 = 25-50 mg/mL). Eptifibatide (8 mg/mL) together with bivalirudin (70 ng/mL, a direct thrombin inhibitor) effectively (approximately 90%) reduced platelet aggregation induced by thrombin (0.2 U/mL). |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Scholz T, Zhao L, Temmler U, et al. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro[J]. Platelets, 2002, 13(7): 401-406. [2]. Ciborowski M, Tomasiak M. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets[J]. Acta poloniae pharmaceutica, 2008, 66(3): 235-242. | |
Quality Control & MSDS
- View current batch:
Chemical structure
